Biotech Stock 2seventy bio, Inc. (Nasdaq: TSVT) Soars on Acquisition News

Biotech Stock 2seventy bio, Inc. (Nasdaq: TSVT) Soars on Acquisition News: Biotech Stock 2seventy bio, Inc. (Nasdaq: TSVT) Soars on Acquisition News

Breaking Medical Technology News: Aethlon Medical (NASDAQ: $AEMD) Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology Journal

 

Breaking Medical Technology News: Aethlon Medical (NASDAQ: $AEMD) Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology Journal

 

Preclinical Data Suggests Expanded Therapeutic Potential of the Hemopurifier® Beyond Virology and Oncology

 

Results Support Further Evaluation of the Hemopurifier® as Part of a Machine Perfusion Circuit to Further Assess its Impact on the Function of Retrieved Kidneys

 

SAN DIEGO, CA - March 10, 2025 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases and for use in organ transplantation, today announced the publication of a pre-clinical study in the peer-reviewed journal Transplant Immunology (https://doi.org/10.1016/j.trim.2025.102215) on February 28, 2025, entitled, "A lectin affinity plasmapheresis device removes extracellular vesicles and microRNAs from renal perfusates following controlled oxygenated rewarming of discarded donor kidneys."

 

Aethlon Medical's Hemopurifier® is a therapeutic blood filtration system designed to bind and remove harmful extracellular vesicles and life-threatening viruses from blood and other biological fluids. Its capabilities have potential applications in oncology and infectious diseases, and organ transplantation.

 

Paid News Dissemination of behalf of AEMD.

 

Read this in full at https://www.investorideas.com/news/2025/03101AEMD-Preclinical-Data-on-Hemopurifier-in-Transplant-Immunology-Journal.asp

 

"Kidney transplantation provides the highest quality of life for those afflicted with end stage renal disease, yet there is a shortage of organs available, and for those who do receive organs, complications may include delayed function and organ rejection," stated Steven LaRosa, MD, Senior Author of the publication and Chief Medical Officer of Aethlon Medical.

 

"The use of machine perfusion of recovered organs as opposed to cold storage has helped but there is still room for improvement. The release of extracellular vesicles (EVs) and microRNAs from the donor kidney are hypothesized to play a role in these complications.

With that in mind, we specifically examined the ability of the Hemopurifier to remove EVs and noxious microRNAs from the perfusion fluid from discarded kidneys that had undergone Controlled Oxygenated Rewarming. We demonstrated significant reductions in EVs as well as microRNAs implicated in renal dysfunction."

 

"While the company's funding and focus are dedicated to the Australian and India Oncology trials, the data generated from this pre-clinical study demonstrates that extracellular vesicle removal as a therapeutic target for the Hemopurifier extends beyond virology and oncology. We believe there exists a "pipeline within a device"," added James Frakes, Chief Executive Officer and Chief Financial Officer of Aethlon Medical. However, we acknowledge that further evaluation is needed, including incorporating the Hemopurifier into a machine perfusion circuit with discarded kidneys followed by a clinical trial. Our technology could be potentially "bolted on" to existing organ preservation technology.

 

About Aethlon and the Hemopurifier®

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to raise additional capital and to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility of the Hemopurifier in removing EVs and microRNAs from renal perfusates; the Company's ability to conduct its planned oncology clinical trials in Australia and India; the Company's ability to manage and successfully complete its current and future clinical trials, if initiated; the Company's ability to conduct clinical trial(s) designed to demonstrate benefits of the incorporation of the Hemopurifier® into renal perfusion; the Company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials, and other potential risks. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2024, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances

.

Additional information can be found at www.AethlonMedical.com.

 

Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

 

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com

 

SOURCE Aethlon Medical, Inc.

 

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

 

More info on AEMD at Investorideas.com Visit: 

https://www.investorideas.com/CO/AEMD/

 

Get News Alerts on Aethlon Medical

 

Disclaimer/Disclosure: Athelon Medical, Inc. (AEMD) is a paid featured  medical tech stock on Investor ideas  More disclosure:Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding specific questions.

 

 

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories

 

Investorideas.com adds New IPOs in Biotech, Technology, Homebuilder, Aerospace, Sports; (Nasdaq: $AARD), (NASDAQ: $SION), (Nasdaq: $NNNN), (NASDAQ: $CJMB), (NASDAQ: $XHLD), (NASDAQ: $ODYS), (NYSE: $TTAM), (NASDAQ: $FBGL), (NYSE: $KRMN), (NASDAQ: $AGH)

 Investorideas.com adds New IPOs in Biotech, Technology, Homebuilder, Aerospace, Sports; (Nasdaq: $AARD), (NASDAQ: $SION), (Nasdaq: $NNNN), (NASDAQ: $CJMB), (NASDAQ: $XHLD), (NASDAQ: $ODYS), (NYSE: $TTAM), (NASDAQ: $FBGL), (NYSE: $KRMN), (NASDAQ: $AGH)  

 

 

 

March 7, 2025 – (Investorideas.com Newswire) Investorideas.com, a recognized top 100 investment site for stock news announces today’s IPO’s  to watch in the Biotech, Technology, Homebuilder, Aerospace and Sporting sectors.

 

New companies are all Nasdaq/NYSE IPOs from February 2025.

 

New stocks added today: Aardvark Therapeutics, Inc. (Nasdaq:AARD), Sionna Therapeutics, Inc. (NASDAQ:SION), Anbio Biotechnology (Nasdaq:NNNN), CALLAN JMB INC. (NASDAQ:CJMB), TEN Holdings, Inc. (NASDAQ:XHLD), Odysight.ai Inc. (NASDAQ:ODYS), Titan America SA (NYSE:TTAM), FBS Global Ltd  (NASDAQ:FBGL), Karman Holdings Inc. (NYSE:KRMN), Aureus Greenway Holdings Inc (NASDAQ:AGH).

 

Read this in full at https://www.investorideas.com/news/2025/main/03071Stocks.asp

 

Investor Ideas is always researching and searching for new stocks to add to our growing list of free stock directories. The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

New Stocks Added to the Biotech Directories:

Aardvark Therapeutics, Inc. (Nasdaq:AARD) is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its portfolio of small molecule programs targets biological pathways associated with alleviating hunger. Aardvark’s lead product candidate, ARD-101, targets Bitter Taste Receptors (TAS2Rs) expressed in the gut lumen, inducing secretion of endogenous signaling molecules, including the satiety hormone cholecystokinin (CCK), which in turn activates gut-brain signals to suppress the sensation of hunger. This potential first-in-class oral investigational drug demonstrated clinical activity and was well-tolerated in Phase 2 trials and has entered Phase 3 development for hyperphagia associated with Prader-Willi Syndrome, for which Aardvark has been granted Orphan Drug Designation. Additionally, Aardvark intends to advance ARD-101 into Phase 2 development for hyperphagia associated with hypothalamic obesity, with a goal of addressing significant unmet needs across both these rare disease indications. Aardvark is also developing ARD-201, which will be a fixed-dose combination of ARD-101 with a dipeptidyl peptidase-4 (DPP-4) inhibitor, with a goal of addressing some of the limitations of currently marketed GLP-1 therapies for the treatment of obesity and obesity-related conditions.

 

Sionna Therapeutics, Inc. (NASDAQ:SION) is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for CF by developing novel medicines that normalize the function of the CFTR protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (NBD1), which the company believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, the company is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function.

 

Anbio Biotechnology (Nasdaq:NNNN) is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. It is an innovation-driven global diagnostic company offering a diverse portfolio of mature diagnostic assays and five key platforms for biomarker detection, including Fluorescent Immunochromatographic Solution (FIA), Chemiluminescent Immunoassay Solution (ChLIA), Polymerase Chain Reaction Solution (PCR), Lateral Flow Assay Solution (LFIA), and Loop-Mediated Isothermal Amplification Solution (LAMP). These solutions cater to point-of-care settings, laboratory, and over-the-counter applications, enabling healthcare providers and patients to access fast, reliable, and cost-effective diagnostic tools. With a strong global presence across the EU, APAC, and the Americas, the Company’s Conformité Européenne (CE)-marked products detect biomarkers associated with critical medical domains, encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Designed for compatibility with multiple sample collection matrices, including serum, plasma, whole blood, feces, urine, and saliva, the product lineup facilitates efficient and reliable diagnostic testing across diverse patient populations and healthcare settings. By prioritizing innovation, affordability, and speed, Anbio aims to transform the global diagnostics landscape, fostering a paradigm shift towards personalized and decentralized diagnostic solutions.

 

CALLAN JMB INC. (NASDAQ:CJMB) is an integrative logistics company empowering the healthcare industry and emergency management agencies through exceptional fulfillment, storage, monitoring, and cold chain logistics services to secure medical materials and protect patients and communities with compliant, safe, and effective medicines. Our combined expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance and emergency preparedness is unparalleled in the industry. We offer the Gold Standard in client experience with customizable interfaces, next-level reliability in shipping and environmental sustainability in our specialty packaging.

 

New Stocks Added to the Tech Directories:

TEN Holdings, Inc. (NASDAQ:XHLD) is a provider of event planning, production, and broadcasting services headquartered in Pennsylvania. The Company mainly produces virtual and hybrid events and physical events. Virtual and hybrid events involve virtual and hybrid event planning, production and broadcasting services, and continuing education services, all of which are supported by the Company's proprietary Xyvid Pro Platform. Physical events mainly involve live streaming and video recording of physical events.

 

Odysight.ai Inc. (NASDAQ:ODYS) is pioneering the Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) markets with its visualization and AI platform. Providing video sensor-based solutions for critical systems in the aviation, transportation, and energy industries, Odysight.ai leverages proven visual technologies and products from the medical industry. Odysight.ai’s unique video-based sensors, embedded software, and AI algorithms are being deployed in hard-to-reach locations and harsh environments across a variety of PdM and CBM use cases. Odysight.ai’s platform allows maintenance and operations teams visibility into areas which are inaccessible under normal operation, or where the operating ambience is not suitable for continuous real-time monitoring.

 

New Stocks Added to the Homebuilder Directories:

Titan America SA (NYSE:TTAM) is a leading vertically integrated, multi-regional manufacturer and supplier of heavy building materials and services operating primarily on the Eastern Seaboard of the United States. As a leading provider of materials that contribute to lower carbon emissions compared to traditional building materials, Titan America serves markets that benefit from population growth, economic growth, and technology and innovation trends that are among the strongest in the United States.

 

FBS Global Ltd  (NASDAQ:FBGL) provides construction and engineering services in Singapore. It undertakes interior fit-out works for institutional, residential, commercial, and industrial building projects. The company also supplies building materials and precast concrete components; recycles construction and industrial wastes; and offers pavement consultancy services.

 

New Stocks Added to the Aerospace Directories:

Karman Holdings Inc. (NYSE:KRMN) specialize in the upfront design, testing, manufacturing, and sale of mission-critical systems for existing and emerging missile and defense, and space programs. Our integrated payload protection, propulsion, and interstage system solutions are deployed across a wide variety of existing and emerging programs supporting important Department of Defense and space sector initiatives

 

New Stocks Added to the Sporting Directories:

Aureus Greenway Holdings Inc (NASDAQ:AGH) owns and operates daily fee golf country clubs in the state of Florida that are designed to appeal to a wide-ranging population. The combination of our strategic locations and approachable golf-courses attracts both local and tourist demographics, allowing us to offer a variety of golf experiences while capturing a broad share of discretionary leisure spending. 

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter (X) https://X.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

 

800 665 0411

 

 

Biotech Stock Chimerix (Nasdaq: CMRX) Soars on Acquisition News

Biotech Stock Chimerix (Nasdaq: CMRX) Soars on Acquisition News: Biotech Stock Chimerix (Nasdaq: CMRX) Soars on Acquisition News

New Biotech Stocks at Investorideas.com; New Biotech Stocks at Investorideas.com; (NYSE American: $CHRO), (OTCQB: $BVAXF; CSE: $BIOV.CN), (NASDAQ: $GRCE), (OTCQB: $MBCOF; TSXV: $MRVL.V), (Nasdaq: $ZVSA), (OTC Pink: $RGBP), (OTCQB: $NRXBF; TSXV: $NRX.V), (NASDAQ: $MTVA)

 New Biotech Stocks at Investorideas.com; New Biotech Stocks at Investorideas.com; (NYSE American: $CHRO), (OTCQB: $BVAXF; CSE: $BIOV.CN), (NASDAQ: $GRCE), (OTCQB: $MBCOF; TSXV: $MRVL.V), (Nasdaq: $ZVSA), (OTC Pink: $RGBP), (OTCQB: $NRXBF; TSXV: $NRX.V), (NASDAQ: $MTVA)

 

 

February 28, 2025 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks added to the biotech stock directory.

 

The newest biotechnology companies are focused on pain alleviation, immunotherapies for infectious disease and cancer treatment, rare and orphan diseases, inflammatory or kidney diseases, Central Nervous System injuries and cardiometabolic diseases.

 

New biotech stocks added include:  Channel Therapeutics Corp. (NYSE American: CHRO), BioVaxys Technology Corp. (OTCQB: BVAXF; CSE: BIOV), Grace Therapeutics, Inc (NASDAQ: GRCE), Marvel Biosciences Corp. (OTCQB: MBCOF; TSXV: MRVL), ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), Regen BioPharma Inc. (OTC Pink: RGBP), NurExone Biologic Inc. (OTCQB: NRXBF) (TSXV: NRX), MetaVia, Inc. (NASDAQ: MTVA).

 

Read this in full at https://www.investorideas.com/news/2025/main/02281Stocks.asp

 

 

Investor Ideas is always researching and searching for new stocks to add to our growing list of free stock directories. The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

New Stocks Added to the Biotech Directories:

Channel Therapeutics Corp. (NYSE American: CHRO) formerly Chromocell Therapeutics Corp. - is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The Company’s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain and post-surgical nerve blocks.

 

BioVaxys Technology Corp. (OTCQB: BVAXF; CSE: BIOV) a company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. DPX™ is a patented antigen delivery platform that can incorporate a range of bioactive molecules to produce targeted, long-lasting immune responses enabled by various formulated components. The DPX platform facilitates antigen delivery to regional lymph nodes and has been demonstrated to induce robust and durable T cell and B cell responses in pre-clinical and clinical studies for both cancer and infectious disease.

 

Grace Therapeutics, Inc (NASDAQ: GRCE) (formerly Acasti Pharma Inc.) is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Grace Therapeutics’ novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Grace Therapeutic’s lead clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection with over 40 granted and pending patents. Grace Therapeutics’ lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. In February 2025, Grace Therapeutics announced that its Phase 3 STRIVE-ON safety trial for GTx-104 met its primary endpoint and provided evidence of clinical benefit over orally administered nimodipine.

 

Marvel Biosciences Corp. (OTCQB: MBCOF; TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a "drug redevelopment" approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought, as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies. Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

 

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs for patients with inflammatory or kidney diseases with high unmet medical needs. We are well positioned in the rapidly emerging inflammasome space with a highly differentiated monoclonal antibody, Inflammasome ASC Inhibitor IC 100, and in kidney disease with phase 2 Cholesterol Efflux MediatorTM VAR 200. The lead indication for IC 100 is obesity with metabolic complications, and for VAR 200, focal segmental glomerulosclerosis (FSGS). Each therapeutic area offers a “pipeline within a product,” with potential for numerous indications. The total accessible market is over $100 billion.

 

Regen BioPharma Inc. (OTC Pink: RGBP) is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders.

 

NurExone Biologic Inc. (OTCQB: NRXBF) (TSXV: NRX) is a pharmaceutical company that is developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA and European agency, European Medicines Agency. The NurExone platform technology is expected to offer novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.

 

MetaVia, Inc. (NASDAQ: MTVA) is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.

 

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter (X) https://X.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

 

800 665 0411

 

 

 

 

 

 

 

 

 

 

 

 

Biotech Stock Enveric Biosciences (NASDAQ: ENVB) Soars on Patent News

Biotech Stock Enveric Biosciences (NASDAQ: ENVB) Soars on Patent News: Biotech Stock Enveric Biosciences (NASDAQ: ENVB) Soars on Patent News

Biotech Stock Organovo Holdings (Nasdaq: ONVO) Soars on Eli Lilly (NYSE: LLY) Deal

Biotech Stock Organovo Holdings (Nasdaq: ONVO) Soars on Eli Lilly (NYSE: LLY) Deal: Biotech Stock Organovo Holdings (Nasdaq: ONVO) Soars on Eli Lilly (NYSE: LLY) Deal

Biotech Stock PepGen Inc. (NASDAQ: PEPG) Makes NASDAQ Top Gainers List on Financial Results and Update

Biotech Stock PepGen Inc. (NASDAQ: PEPG) Makes NASDAQ Top Gainers List on Financial Results and Update: Biotech Stock PepGen Inc. (NASDAQ: PEPG) Makes NASDAQ Top Gainers List on Financial Results and Update

Investor Ideas New Stocks to Watch in Life Sciences and AI; (TSXV: $ZCT.V) (TSXV: $IOT.V) (Nasdaq: $SPRC) (OTCQB: $BIXT) (NASDAQ: $KITT) (TSX-V: $XBOT.V; OTC: $XBOTF) (OTCQB: $WYTC) (OTCQB: $RELT)

 Investor Ideas New Stocks to Watch in Life Sciences and AI; (TSXV: $ZCT.V) (TSXV: $IOT.V) (Nasdaq: $SPRC) (OTCQB: $BIXT) (NASDAQ: $KITT) (TSX-V: $XBOT.V; OTC: $XBOTF) (OTCQB: $WYTC) (OTCQB: $RELT)

 

 

February 14, 2025 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the Life Sciences and AI sectors.

 

The newest life sciences companies are involved in woman’s health, microbiology testing, cannabinoid pharmaceuticals and drug development using AI.

 

The latest AI companies are involved in autonomous robotics, AI/sensor technology and marketing and business solutions.

 

New stocks added today: Zero Candida Technologies Inc. (TSXV:ZCT), Innovotech, Inc. (TSXV: IOT), SciSparc Ltd. (Nasdaq: SPRC), Bioxytran, Inc. (OTCQB: BIXT) Nauticus Robotics, Inc. (NASDAQ:KITT), Realbotix Corp. (TSX-V: XBOT; OTC: XBOTF), Wytec International, Inc. (OTCQB: WYTC), Onar, Inc. (OTCQB: RELT).

 

Read this in full at https://www.investorideas.com/news/2025/main/02141Stocks.asp

 

 

Investor Ideas is always researching and searching for new stocks to add to our growing list of free stock directories. The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

New Stocks Added to the Life Sciences/Biotech Directories:

Zero Candida Technologies Inc. (TSXV:ZCT) is a publicly traded FemTech company pioneering innovative solutions in women's health. The company is developing an AI-driven, tampon-like device that uses a therapeutic light source with a selected wave-length and intensity to effectively treat the Candida fungus with a demonstrated 99.999% success rate in POC.  Vulvo-Vaginal Candidiasis ("VVC") affects about 75% of women globally, with 138witheach year 138 million women are affected world-wide and 492 million over their lifetime. Recurrent VVC (4 or more episodes per year) is increasingly documented to become drug resistant to existing treatments, since the root cause is poorly understood and addressed.  ZCT has successfully completed a safety trial using its pre-clinical device in large animals (sheep), and is finalizing their device for human use in preparation for an upcoming clinical trial, that they secured both funding and agreements with leading hospitals in Israel and Europe for. The Company continues to grow it's global patent portfolio with applications filed in the United States, Brazil and Europe, and was recently granted a final patent in South Africa. With hybrid medicine and technology-based diagnostics, ZCT is addressing unmet needs in women's healthcare and expanding access to underserved populations, bringing the field of gynecology into the 21st century.

 

Innovotech, Inc. (TSXV: IOT) is a Canadian biotechnology company owning proprietary intellectual property, conducting contract research, and owning and providing proprietary devices for testing in multiple applications in microbiology

 

SciSparc Ltd. (Nasdaq: SPRC) is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace.

 

Bioxytran, Inc. (OTCQB: BIXT) is a clinical stage biotechnology company pioneering a library of novel complex carbohydrate structures using artificial intelligence software that interprets the Nuclear Magnetic Resonance imaging of druggable targets like the galectin fold to create a rational drug design. The leading drug candidates vetted by in vitro testing, are capable of neutralizing viruses. The peer-reviewed discovery of the galectin fold located on the spike proteins of viruses such as COVID-19, RSV, and H1N1 demonstrate there exists a conserved region on the spike in which Bioxytran’s molecules achieve virus neutralization. The extent of the carbohydrate structure’s ability to neutralize untested viruses is unknown just like the initial discovery of antibiotics last century and its ability to treat a broad spectrum of bacterial infections. Applications of this platform technology extend to the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran’s other development programs are for pulmonary fibrosis and stroke treatment.

 

New Stocks Added to the AI/Tech Directories:

Nauticus Robotics, Inc. (NASDAQ:KITT) develops autonomous robots for the ocean industries. Autonomy requires the extensive use of sensors, artificial intelligence, and effective algorithms for perception and decision allowing the robot to adapt to changing environments. The company's business model includes using robotic systems for service, selling vehicles and components, and licensing of related software to both the commercial and defense business sectors. Nauticus has designed and is currently testing and certifying a new generation of vehicles to reduce operational cost and gather data to maintain and operate a wide variety of subsea infrastructure. Besides a standalone service offering and forward-facing products, Nauticus' approach to ocean robotics has also resulted in the development of a range of technology products for retrofit/upgrading traditional ROV operations and other third-party vehicle platforms. Nauticus' services provide customers with the necessary data collection, analytics, and subsea manipulation capabilities to support and maintain assets while reducing their operational footprint, operating cost, and greenhouse gas emissions, to improve offshore health, safety, and environmental exposure.

 

Realbotix Corp. (TSX-V: XBOT; OTC: XBOTF; FSE: 76M0.F) Transcending the barrier between man and machine, Realbotix creates customizable, full-bodied, humanoids with AI integration that improve the human experience through connection, learning and play. Manufactured in the USA, Realbotix has a reputation for having the highest quality humanoid robots and the most realistic silicone skin technology. Realbotix sells humanoid products with embedded AI to enable human-like social interactions and intimate connections with humans. Our integration of hardware and AI software results in the most human looking full-sized robots on this planet. We achieve this through patented technologies that deliver human-like appearance and movements. This versatility makes our robots and their personalities customizable and programmable to suit a wide variety of use cases.

 

Wytec International, Inc. (OTCQB: WYTC) is a 5G network development company with proprietary, patent, and patent-pending AI/sensor technology designed to support gunshot detection, drug sensing technology for public safety, and distance learning solutions for schools and cities.

 

Onar, Inc. (OTCQB: RELT) is a dynamic marketing and business solutions network, currently publicly traded as Reliant Holdings, Inc. with plans to become Onar Holding Corporation in the near future. ONAR's mission is to provide unparalleled service through an integrated, AI-driven approach, leveraging its diverse brand family's strengths. Committed to honor, candor, and best-in-class results, ONAR aims to lead the industry by example, ensuring every client relationship is deeply rooted in trust and excellence.

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter (X) https://X.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

 

800 665 0411